Micro-positron emission tomography imaging studies were conducted to characterize modulation of metabotropic glutamate subtype-5 receptor (mGluR5) function in a 6-hydroxydopamine (6-OHDA)induced rat model of Parkinson's disease using four analogical PET ligands: 2-
Introduction
Metabotropic glutamate receptors (Catania et al, 1994) are functional components of the glutamatergic system (Krieger et al, 2000; Meldrum, 2000) . These receptors are affected on several intracellular signal transduction mechanisms through G-proteins, having various physiological functions in the mammalian central nervous system (Bruno et al, 2001) . According to their signal transduction mechanism, amino-acid sequence homologies, and pharmacological properties, metabotropic glutamate receptors have been identified as having eight subtypes, divided into three groups (Conn and Pin, 1997; Bhave et al, 2003; Schaffhauser et al, 2003) . The metabotropic glutamate subtype-5 receptors (mGluR5s) are included in the first group. It has been reported that many neurological disorders such as Parkinson's disease (PD), Schizophrenia, mood disorders, drug addiction, and pain might be affected by the direct or indirect effects of mGluR5s. Metabotropic glutamate subtype-5 receptors have also been tested as potential neuroprotective drugs (Chiamulera et al, 2001; Marino et al, 2003; Sotgiu et al, 2003; Brody and Geyer, 2004) .
Increased glutamatergic activity in the basal ganglia circuitry is involved in movement abnormalities in PD (Wichmann and DeLong, 1997) . The mGluR5s are implicatively connected to the subthalamic nucleus from glutamatergic afferents (Awad et al, 2000) . The mGluR5s are localized in cholinergic striatal neurons (Marti et al, 2001; Bell et al, 2002) , whose excessive excitation was observed in the basal ganglia. Therefore, inhibition of mGluR5 binding has been proposed as a therapeutic approach for PD Breysse et al, 2002; Coccurello et al, 2004) .
In this study, modulation of mGluR5s was investigated in 6-hydroxydopamine (6-OHDA) lesioned rat brain by in vivo positron emission tomography (PET) imaging using four pyridine derivatives: [ 11 C]MPEP, [ 11 C]M-MPEP, [ 11 C]M-PEPy (Yu et al, 2005) , and [ 18 F]M-TEP.
6-Hydroxydopamine is a selective catecholaminergic neurotoxin (Ungerstedt, 1968; Sachs and Jonsson, 1975) and it is structurally similar to dopamine (DA). 6-Hydroxydopamine can be taken up by the DA transporters and concentrated in DA cells, resulting in degeneration of DA neurons. Various PD models in different species such as rodents and small monkeys have been developed by the injection of 6-OHDA into the substantia nigra, medial forebrain bundle, or intrastriatal locations (Breese and Breese, 1998; Shults et al, 2000; Kirik et al, 2001; Betarbet et al, 2002; Zafar et al, 2003) . A noticeable benefit of applying unilateral lesioning is that the loss of DA neurons in the lesion side can be investigated by comparing with the intact part on the contralateral side.
In this study, the rat model of PD was induced by unilateral stereotaxic 6-OHDA injection into the right side of the medial forebrain bundle. The severity of the lesion was determined by PET imaging of DA transporter binding using [ 11 C]CFT, a selective and sensitive ligand for DA transporter (Brownell et al, 1996) . After PET imaging with mGluR5 ligands and [ 11 C]CFT binding potential images were processed using a modified graphical method of Logan (Logan et al, 1990 (Logan et al, , 1996 Logan, 2000) . In addition, representative regions of interests (ROIs) were drawn to the left and right brain areas on the original images of activity distribution. Time-dependent activity curves were processed and used in the graphical method to determine local binding characteristics to investigate 6-OHDAinduced differences between the right and left brain areas, including striatum, hippocampus, and cortex.
Materials and methods

6-Hydroxydopamine Rat Model
Nine male Sprague-Dawley rats (weigh between 300 and 350 g) were anesthetized with ketamine (80 mg/kg intraperitoneal) and xylazine (10 mg/kg intraperitoneal), and placed into the Kopf stereotaxic frame. To restrict the effect of 6-OHDA on the dopaminergic neurons, the animals received desipramine (20 mg/kg intraperitoneal) 30 mins before the 6-OHDA injection. A unilateral injection of 6-OHDA (8 mg in 2 mL) was conducted into the medial forebrain bundle on the right side of the rat brain (coordinates: AP À4.5; ML + 1.2; DV À7.6) using a Hamilton syringe (Cicchetti et al, 2002) . All experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Policy by the Subcommittee on Research Animals of the Harvard Medical School and Massachusetts General Hospital.
Radioligands
The radiosyntheses of [ 11 C]MPEP, [ 11 C]M-MPEP, and [ 11 C]M-PEPy were performed according to Yu et al (2005 Yu et al ( , 1999 . For the radiosynthesis of [ 18 F]M-TEP, the precursor 2-bromo-5-(2-(2-methylthiazol-4-yl)ethynyl)pyridine (B2.0 mg) was added to the dried [ 18 F]fluoride/Kryptofix 2.2.2 vial with dry dimethylsulfoxide (0.5 mL). The vial was heated at 1001C for 10 mins. After cooling for 5 mins, a sample was taken to radio thin layer chromatography, showing that 72% of the radioactivity was in the desired product, 2-[ 18 F]fluoro-5-(2-(2-methylthiazol-4-yl)ethynyl)pyridine, that is, [ 18 F]M-TEP, and the product was identified with an authentic reference standard. The reaction mixture was diluted with 3 ml ethyl acetate, loaded to a silica Sep-Pak, and eluted with an additional 5 ml ethyl acetate. The ethyl acetate solution was evaporated at 1301C under a N 2 flow. The residue (B0.5 mL) was cooled for 5 mins, diluted with high-performance liquid chromatography solvent (1.5 mL), and transferred to a highperformance liquid chromatography injection vial. By using a m-Bondapak column and a mobile phase of 40% methanol and 60% phosphate buffer (pH 7.4, 0.15 mmol/L), the pure tracer [ 18 F]M-TEP was isolated.
Radiosynthesis of [ 11 C]CFT was performed according to Brownell et al (1996) .
Positron Emission Tomography Imaging
Forty-five PET imaging studies were conducted in nine 6-OHDA-lesioned rats. After a rat was anesthetized by gas (1% to 1.5% isoflurane, 2% nitrous oxide, and oxygen flow of 3 L/min), the tail vein was catheterized for administration of radiolabeled ligands. The head was adjusted securely in a stereotaxic head holder equipped with a gas inhalation system. Then the rat was placed ventrally into the scanner at the center of the imaging field, where the spatial resolution is 1.8 mm (microPET, P4, Concorde Microsystems, Knoxville, TN, USA). A heated waterbed and an infrared light were used to maintain body temperature. Heart rate was monitored during the whole imaging time (HESKA Vet/Ox Plus 4800). Before administering radioactivity, a transmission imaging was conducted using a rotating germanium-68 pin source to create maps for attenuation correction. After that, a radiolabeled ligand was injected into the tail vein and volumetric dynamic data were acquired in list-mode format for 60 mins. Dopamine transporter binding was investigated with [ 11 C]CFT and studies were conducted twice on each animal. The severity of the lesion was investigated 2 weeks after 6-OHDA lesioning and 4 weeks later, at the time of the studies of mGluR5 function to accurately determine dopaminergic deficit. The mGluR5 binding was investigated with [ 11 C]MPEP in each animal and repeated in two rats, [ 11 C]M-MPEP in six rats, [ 11 C]M-PEPy in seven rats, and [ 18 F]M-TEP in three rats.
Image Analysis
Dynamic imaging data were corrected for uniformity, attenuation, and decay factors, and processed by filtered back projection with the ramp filter (cutoff value of 0.5). The software, ASIPro 6.0, was provided by the manufacturer. The binding characteristics of the PET ligands were analyzed using a modified distribution volume (DV) method of Logan (Logan et al, 1990 (Logan et al, , 1996 Logan, 2000) . The Logan linear model has become a standard analyzing method for receptor-ligand studies to determine the DV of ligands, which have reversible binding kinetics. If the metabolite corrected plasma data are available, the DVs can be calculated from the region of interest and reference blood data to obtain the distribution volume ratio (DVR). If metabolite corrected plasma curves are not available, the plasma curve can be replaced with the reference region curve C r (t) as long as the reference region is considered receptor-free. The slope of the linear phase is DVR with the following formula:
where C t (t) is the radioactivity measured by the PET at time t in a specified area (single pixel or averaged ROI over the selected pixels) and C r (t) is the radioactivity in reference region curve at time t. For time T > t*, the DVR can be found as the slope of a plot of
and the ratio of C t (t)/C r (t) stays stable. The time t* can be determined as the time after which no further significant increase in the slope is observed. The binding potential (BP) values can be obtained as BP = DVRÀ1. In practice, considering the noncontinuousness of time-dependent activity curves obtained from dynamic PET images, equation (1) has to be modified as
where Dt is the time interval for time-dependent activity curves. Assuming that cerebellum has 0 or almost 0 receptor density, the slopes, that is DVRs, can be obtained by graphical fitting (Figure 3 ).
When calculating BP images, the voxels outside the head were eliminated by using binary 3D images as space filters. Each filter was created separately from the coronal slices of the original dynamic volumetric images by adding images between 5 and 15 mins to create a static summary image. After thresholding, these images were converted to binary images having a value of 1 for the data inside the head and 0 outside the head. The original images were multiplied with this filter and used in further calculations of binding values on pixel-by-pixel bases by using equation (2) (Figure 3) . The total number of the calculated voxels was 10^5 and the calculation speed was 406 voxels/sec by using x86-based PC with 1,395 MHz processor.
Two methods were applied for drawing the regions of interest on the PET images. If the studies with an mGluR5 ligand and [ 11 C]CFT were performed in the same imaging session, the ROIs were drawn on [ 11 C]CFT images and the same ROIs were directly loaded to the PET images of the mGluR5 ligand. This type of sequential imaging allows analyses of the same brain regions and enables accurate local comparison of the mGluR5 and DA transporter data, as long as there is no movement of animals during the acquisition of PET data.
The other method includes fusing the mGluR5 images to [ 11 C]CFT images on the same rat. The merging procedure was performed manually on a pixel-by-pixel basis by using the Harderian glands, the olfactory bulb, and the whole-brain contours as internal markers. After the fusion procedures of the mGluR5 and DA transporter images, ROIs were drawn on the [ 11 C]CFT images and applied to the PET images of the mGluR5 ligands. Regions of interests were drawn on the right and left striatum, cortex, hippocampus, and cerebellum, and the corresponding time-dependent activity curves were processed.
Percent differences of the right-left regions were calculated for striatum, hippocampus, and cortex by the following equation:
Thus, the percent difference ( 
Statistical Analysis and P-value
The statistical significance of the changes between the right and left brain areas was calculated using a paired t-test (Whitley and Ball, 2002) (Table 1 ). The used t-test compares the observed mean difference (f) with the hypothesized value of 0. The t-statistic for the paired t-test is
where s.d. is the standard deviation. Significance was determined based on t-distribution. Practically, the Pvalues were calculated directly using the t-test function in Microsoft Excel 2002 SP3. Time-activity curves were generated from several brain areas including cerebellum, right and left striatum, hippocampus, and cortex (Figure 2A) . The number of the voxels included to the ROIs was 155743 for the left striatum, 119739 for the right striatum, 103727 for the left hippocampus, 102722 for the right hippocampus, 66722 for the left cortex, 69720 for the right cortex, and 96720 for the cerebellum. The corresponding Logan plots of these curves are shown in Figure 2B . The straight lines (Logan plots) were obtained using equation (2) with T = 10 mins. For all compounds, the Logan plots show linearity starting at 10 mins after injection of the ligand. Figure 3 shows the BP images for the DA transporter ligand [ 11 C]CFT and four mGluR5 ligands with the PET images in Figure 1 . By comparing Figures 1 and 3 , it is observed that the BP images of each ligand have higher contrast than the corresponding PET images of activity distribution.
Results
The percent differences between the right and left brain areas were calculated using equation (3), and the values (f, s.d., and P) for the striatum, hippocampus, and cortex are shown in Figure 4 and Table 1 . [ 11 C]CFT binding was decreased on the lesioned striatum (right side) by 35.4%713.4% compared with the left intact side, indicating a corresponding loss of presynaptic DA terminals. In contrast, on the same area of the lesioned striatum, three of four tested mGluR5 ligands showed increased binding. The average differences of DVR between the right and left striatum were 4.4%7 6.5% (P < 0.05) with [ 11 C]MPEP, À0.1%71.7% (P > 0.05) with [ 11 C]M-MPEP, 3.9%74.4% (P < 0.05) with [ 11 C]M-PEPy, and 6.6%72.7% (P > 0.05) with [ 18 F]M-TEP. In the hippocampus, the percent differences between the right and left sides were 6. Table 1 .
Discussion
The pyridine derivatives used to investigate mGluR5 function have a reversible binding profile with maximum binding in 1 to 3 mins. Rapid changes in the accumulation of the activity in small brain areas create significant fluctuation of data and cause difficulties in direct mathematical fitting using a three-compartment model. For that reason, we developed a modified graphical model of the Logan method for data analysis (Logan et al, 1990 (Logan et al, , 1996 Logan, 2000) . To increase the accuracy of the outcome measures from the same rat, we used cerebellum as a reference tissue, as the selection of the region is repeatable; based on in situ hybridization histochemical and immunohistochemical studies, adult rat brain has only weak expression of mGluR5 in Golgi cells and cerebellar nuclei in the cerebellum (Shigemoto and Mizuno, 2000) . As observed in Figure 2A , each mGluR5 ligand has faster washout from each brain area than [ 11 C]CFT. Owing to the low contrast in the PET images of mGluR5 ligands, it is difficult to draw representative anatomical borderlines of striatum, hippocampus, cortex, or cerebellum. Instead, using the [ 11 C]CFT images, it is easy to segment these areas as shown in Figure 1 . For this reason, the ROIs in PET images of mGluR5 were obtained from [ 11 C]CFT studies. When ]M-TEP in the 6-OHDAlesioned rat brain processed pixel-by-pixel basis using a modified Logan graphical method. The first column of the coronal images is at the striatum level, the second at the hippocampus level, and the third at the cerebellum level. The axial views illustrate the distribution of the radioactivity at the midstriatal level. All these levels are exactly the same as shown in Figure 1 .
the PET studies of DA transporters with [ 11 C]CFT were performed in the same imaging session as mGluR5 studies, the ROIs were extracted from [ 11 C]CFT images and used in both studies. When the studies were performed in different imaging sessions, the anatomical landmarks of Harderian glands, olfactory bulbs, and whole-brain contours were used as internal markers, and the images of mGluR5 ligands and [ 11 C]CFT were fused on pixelby-pixel basis. The ROIs determined from [ 11 C]CFT images were used in both studies. This allows precisely the same anatomical localization to be applied for generation of the quantitative data in both studies.
Partial volume effect results from the limited spatial resolution of PET imaging. It may cause significant underestimation in the measurement of radioactivity concentration in small brain areas, and furthermore creates systematic errors in evaluating quantitative physiological parameters (Hoffman et al, 1979) . In our studies, there are two aspects that may suppress the partial volume effect systematic errors: one is the use of cerebellum as the reference tissue in equation (2); the other is the comparison of the right (lesioned) and the left (control) brain regions of the same rats by calculating percent differences in equation (3). The average difference between the selected number of the voxels on the right and left brain regions is 1 to 4 voxels. In addition, the same ROIs on the left and right sides were used to obtain data of DA transporter and mGluR5 ligands. Therefore, partial volume effect is not currently considered as a major effect on our results.
As shown in Figure 2A , the accumulation of [ 11 C]MPEP, [ 11 C]M-MPEP, and [ 11 C]M-PEPy achieved the maximum value within 1 min after injection of the activity and then decreased to the same level as cerebellum in about 15 mins, whereas [ 18 F]M-TEP achieved its peak accumulation within about 3 mins and decreased to the cerebellum level in about 18 mins. After 20 mins, mGluR5 ligands have only minor differences in accumulation of the right and left striatum and hippocampus. With the exception of the plots of the right striatum and hippocampus with [ 11 C]MPEP and [ 11 C]M-PEPy, the Logan plots showed good linearity when T was set to 10 mins. The areas of right-side striatum and hippocampus were directly affected by 6-OHDA lesioning, which might affect the binding mechanism of MPEP and M-PEPy. After setting T to 15 min or 20 mins, a better linearity of Logan plots was obtained in these brain areas.
The aim of these studies was to compare four mGluR5 ligands to characterize 6-OHDA-induced modulation of the function of the metabotropic glutamate subtype-5 receptors in rat brain. Based on Logan graphic method (equation (1)), the values of DVRs as shown in Figure 2B can express modulation of mGluR5 function as numeric binding parameters. Therefore, the differences in the accu-mulation between 6-OHDA lesioned and control brain areas can be obtained simply by calculating the percent difference as shown in Eq. (3).
As displayed in Figure 4 and Table 1 , the percent differences of four mGluR5 ligands indicate enhanced glutamatergic function around the 6-OHDAaffected regions, whereas the percent differences of the DA transporter ligand indicate the severity of the 6-OHDA-induced lesion in the same site. These results are consistent with PET images of activity distribution (Figure 1) and BP (Figure 3) . Taken together, these results indicate a complementary role of metabotropic glutamine subtype-5 receptors during or after dopaminergic degeneration. In other words, the 6-OHDA-lesioned areas in the rat brain have enhanced function of the metabotropic glutamine receptors, and this increase may compensate the effect of dopaminergic degeneration. Earlier in vitro studies have shown that rat striatal mGluR5 exerts a direct control on the phosphorylation of transmembrane DA transporter protein by decreasing the efficiency in re-uptake/release of DA at the presynaptic terminals (Page et al, 2001) .
Although the same dose of 6-OHDA was injected into each rat, the loss of presynaptic DA terminals in individual rats was not the same. The s.d. was 13.4% as shown in Figure 4 and Table 1 . It should be noted that the microPET P4 system is stable and the experimental imaging techniques are well defined and they do not contribute to such large deviation. The individual discrepancy of degeneration in presynaptic DA terminals might be caused by individual differences of the animals, including their head size, their health status, and ability to recover. It is reasonable to believe that the individual variances of the sizes of brains might cause a little excursion on the localization when researchers were positioning the injection sites for 6-OHDA by the Kopf stereotaxic frame.
The average percent differences between the brain areas were analyzed statistically and their P-values were compared with 0.05 or 0.005. The results are tabulated in Table 1 . In addition, Figure 4 and Table 1 show that the mGluR5 ligands have different binding profiles in different brain areas. This might result from the different lipophilicity, molecular size, and polarity of the ligands (Cosford et al, 2003; Yu et al, 2005) . All four mGluR5 ligands are pyridine derivatives with high specific radioactivity and high radiochemical purity. Three of the four ligands showed enhanced glutamatergic function in the right-side lesioned striatum, hippocampus, and cortex of the rat model of PD, although their binding values were different.
Based on the percent differences of the binding values between the right and left striatum, the investigated pyridine derivatives can be ranked in the following order: [ 18 F]M-TEPB[ 11 C]MPEP > [ 11 C]M-PEPy > [ 11 C]M-MPEP. However, studies with [ 18 F]M-TEP were conducted in only three animals and the obtained percent differences were not significant (P > 0.05) for the three brain areas because of the small sample number. The advantage of [ 18 F]M-TEP over the three other ligands is that the radiolabeled fluorine-18 (T 1 2 = 110 mins) allows transportation of the labeled ligand to users who do not have an accelerator in the proximity.
PET studies of DA transporter function were performed twice on each animal. The first study was performed 2 weeks after 6-OHDA administration to determine the immediate extent of the induced lesion and the second study 4 weeks later to accurately determine dopaminergic deficit at the time of the mGluR5 studies. There were no significant differences between the two imaging studies of DA transporter function, indicating that the 6-OHDA-induced lesion was stable during the 4-week research period.
In summary, the graphical analyses based on Logan plots can be used to analyze binding characteristics of mGluR5 ligands: 
